ASXL1 and myelodysplastic syndrome: In a retrospective study of 40 patients, ASXL1 mutations predicted a favorable response and survival after venetoclax and HMA therapy in patients with myelodysplastic syndromes (MDS) with excess blasts (EB), with rates of complete remission of 92% for patients with ASXL1 mutation vs. 57% for those without [74].